Vasogen Inc.

Contact:
Glenn Neumann, Investor Relations
2505 Meadowvale Blvd.
Mississauga, ON, Canada L5N 5S2
tel: (905) 817-2004  fax: (905) 569-9231
www.vasogen.com / investor@vasogen.com

--------------------------------------------------------------------------------

FOR IMMEDIATE RELEASE

          Vasogen to Present at Rodman & Renshaw Healthcare Conference

Mississauga, Ontario (November 1, 2006) -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS),
a leader in the research and commercial development of technologies targeting
the chronic inflammation underlying cardiovascular and neurological disease,
today announced that its President and Chief Executive Officer, David Elsley,
will present a Company overview at the Rodman & Renshaw
 8th Annual Healthcare Conference on Wednesday, November 8, at 3:30 p.m. ET, at
The New York Palace Hotel in New York City.

A live audio web cast and slide presentation of the event can be accessed
through Vasogen's web site at: www.vasogen.com. An archived replay will be
available following the presentation.

About Vasogen:

Vasogen is focused on the research and commercial development of technologies
targeting the chronic inflammation underlying cardiovascular and neurological
disease. Vasogen's Celacade(TM) technology is in late-stage development for the
treatment of chronic heart failure. The recently completed phase III ACCLAIM
trial assessed the impact of Celacade on reducing the risk of mortality and
morbidity in patients with Class II-IV systolic heart failure. Vasogen is also
developing a new class of drugs for the treatment of neuro-inflammatory and
neuro-vascular disorders. VP025, which is entering phase II clinical
development, is the lead product candidate from this new class of drugs.

Certain statements contained in this press release,  upcoming  presentation,  or
elsewhere in our public documents constitute "forward-looking statements" within
the meaning of the United States  Private  Securities  Litigation  Reform Act of
1995.  These  statements may include,  without  limitation,  summary  statements
relating to results of the ACCLAIM trial in patients with chronic heart failure,
plans to advance the  development  of  Celacade(TM),  statements  concerning our
partnering  activities  and  health  regulatory  submissions,  strategy,  future
operations,   future  financial  position,  future  revenues,  projected  costs,
prospects,  plans and objectives of management.  In some cases, you can identify
forward-looking  statements  by  terminology  such as "may",  "will",  "should",
"expects",  "plans",   "anticipates",   "believes",   "estimated",   "predicts",
"potential",  "continue",  "intends",  "could", or the negative of such terms or
other  comparable  terminology.  A number of assumptions  were made by us in the
preparation of these forward-looking statements, including assumptions about the
nature,  size and  accessibility  of the market for Celacade in the treatment of
chronic heart failure,  particularly in Europe, the regulatory  approval process
leading to commercialization and the availability of capital on acceptable terms
to pursue the  development  of Celacade.  You should not place undue reliance on
our  forward-looking  statements  which are subject to a multitude  of risks and
uncertainties that could cause actual results, future circumstances or events to
differ materially from those projected in the forward-looking statements.  These
risks  include,  but are not limited to, the outcome of further  analysis of the
ACCLAIM  trial  results,  the  requirement  or  election  to conduct  additional
clinical trials, delays or setbacks in the regulatory approval process, securing
and maintaining  corporate  alliances,  the need for additional  capital and the
effect of capital market  conditions and other factors on capital  availability,
the potential dilutive effects of any financing, including the convertible notes
we issued in October 2005, risks associated with the outcome of our research and
development programs,  the adequacy,  timing and results of our clinical trials,
competition,  market acceptance of our products,  the availability of government
and  insurance  reimbursements  for our products,  the strength of  intellectual
property,   reliance  on  subcontractors  and  key  personnel,   losses  due  to
fluctuations in the  U.S.-Canadian  exchange rate, and other risks detailed from
time to time in our  public  disclosure  documents  or  other  filings  with the
Canadian and U.S. securities  commissions or other securities regulatory bodies.
Additional risks and uncertainties  relating to our Company and our business can
be found in the "Risk Factors"  section of our Annual  Information Form and Form
40-F for the year  ended  November  30,  2005,  as well as in our  later  public
filings.  The forward-looking  statements are made as of the date hereof, and we
disclaim any  intention  and have no  obligation  or  responsibility,  except as
required by law, to update or revise any forward-looking statements,  whether as
a result of new  information,  future  events  or  otherwise.  Unless  otherwise
indicated, numerical values indicating the statistical significance ("p-values")
of results  included in this  document are based on analyses that do not account
for endpoint multiplicity.